Comparison of the Sensitive Cutaneous Block Distribution Following Femoral Nerve Block Using Two Femoral Block Techniques

NCT ID: NCT02721290

Last Updated: 2019-08-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-01-31

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, we will be comparing two approaches to the femoral block. The first or classical approach and one that is the most popular in our institution is used by combining ultrasound guidance and neurostimulator to do the block. The second is performed with the ultrasound alone aiming at the inferolateral aspect of the femoral artery with the needle and injecting. The primary endpoint of the study is the sensitive cutaneous block distribution using both techniques.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Regional Anesthesia Femoral Nerve Block

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Femoral nerve block using Ultrasound and neurostimulator

Femoral block using the standard technique of ultrasound for femoral nerve identification and neurostimulator set at between 0.3-0.5 mA with quads muscle response for needle placement confirmation before injecting 20cc of Ropivacaine 0.5%.

Group Type ACTIVE_COMPARATOR

Femoral nerve block using Ultrasound and neurostimulator

Intervention Type PROCEDURE

Ropivacaine 0.5%

Intervention Type DRUG

Ropivacaine 0.5% (20cc total) will be injected for the performance of the block in the two arms of the study.

Femoral nerve block using femoral artery target

Femoral block using the alternate technique of aiming for the inferolateral aspect of the femoral artery and injecting 20cc of Ropivacaine 0.5%.

Group Type EXPERIMENTAL

Femoral nerve block using Ultrasound

Intervention Type PROCEDURE

Ropivacaine 0.5%

Intervention Type DRUG

Ropivacaine 0.5% (20cc total) will be injected for the performance of the block in the two arms of the study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Femoral nerve block using Ultrasound and neurostimulator

Intervention Type PROCEDURE

Femoral nerve block using Ultrasound

Intervention Type PROCEDURE

Ropivacaine 0.5%

Ropivacaine 0.5% (20cc total) will be injected for the performance of the block in the two arms of the study.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients scheduled for an elective surgery for which the anesthesiologist planned to do a single shot or continuous femoral nerve block.

Exclusion Criteria

* Any contraindication to the femoral nerve block (coagulopathy, infection, pre-existing neuropathy, local anesthetic allergy and refusal of local anesthesia).
* Refusal to participate in the study
* Inability to understand or communicate the effect of local anesthesia secondary to the femoral nerve bloc.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Maisonneuve-Rosemont Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Issam TANOUBI

Associate professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hopital Maisonneuve-Rosemont

Montreal, Quebec, Canada

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Canada

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Issam Tanoubi, MD

Role: CONTACT

1 844 634-3400 ext. 3808

Cédric Godbout-Simard, MD

Role: CONTACT

1 844 634-3400 ext. 3808

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Cédric Godbout-Simard, MD

Role: primary

5147151723

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20160112

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

High Versus Low Adductor Canal Block
NCT04155983 UNKNOWN PHASE4